Towards customized cancer vaccines: a promising filed in personalized cancer medicine

References

• Dalgleish AG. Cancer vaccines as a therapeutic strategy. Expert Rev Vaccines. 2004;3(6):665–668.
   PubMedGoogle Scholar
• Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: looking to the future. Oncoimmunology. 2013;2(3):e23403.
   PubMed Web of Science ®Google Scholar
• Thomas S, Prendergast GC. Cancer Vaccines: a Brief Overview. Methods Mol Biol. 2016;1403:755–761.
   PubMedGoogle Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–915.
   PubMed Web of Science ®Google Scholar
• Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–1647.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712.
   PubMed Web of Science ®Google Scholar
• Crombet Ramos T, Rodriguez PC, Neninger Vinageras E, et al. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14(10):1303–1311.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Popa X, Martinez O, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 2016;22(15):3782–3790.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–642.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van Den Eynde BJ, Van Der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–146.
   PubMed Web of Science ®Google Scholar
• Chomez P, De Backer O, Bertrand M, et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61(14):5544–5551.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30.
   PubMed Web of Science ®Google Scholar
• Vigneron N, Ooms A, Morel S, et al. Van Den Eynde BJ. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun. 2002;2:9.
   PubMedGoogle Scholar
• Linnebacher M, Gebert J, Rudy W, et al. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001;93(1):6–11.
   PubMed Web of Science ®Google Scholar
• Linnemann C, Van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015;21(1):81–85.
   PubMed Web of Science ®Google Scholar
• OSE Immunotherapeutics Developing Tedopi to jump-start cytotoxic T-cell response in lung cancer fight. Retrieved 2019 Aug 26, from https://wxpress.wuxiapptec.com/ose-immunotherapeutics-developing-tedopi-to-jump-start-cytotoxic-t-cell-response-in-lung-cancer-fight/.).
   Google Scholar
• Giaccone G,Felip E, Cobo M, et al. Activity of OSE-2101 in HLA-2A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): step1 results of Phase 3 Atalante-1 randomised tial, In: Abstract #1260MO, 2020, Virtual 2020 Presidential Symposium, Septemper 19-21, 2020. Switzerland (2020).
   Google Scholar
• Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants–recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol. 2015;37(1):1–11.
   PubMed Web of Science ®Google Scholar
• Ignacio BJ, Albin TJ, Esser-Kahn AP, et al. Toll-like receptor agonist conjugation: a chemical perspective. Bioconjug Chem. 2018;29(3):587–603.
   PubMed Web of Science ®Google Scholar
• Wong KK, Li WA, Mooney DJ, et al. Advances in therapeutic cancer vaccines. Adv Immunol. 2016;130:191–249.
   PubMed Web of Science ®Google Scholar
• Moser C, Müller M, Kaeser MD, et al. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12(7):779–791.
   PubMed Web of Science ®Google Scholar
• Davis I, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America.2004;101(29):10697-702.
   Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6(232):232ra251–232ra251.
   Web of Science ®Google Scholar
• Speiser DE, Liénard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115(3):739–746.
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8):1254–1261.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847.
   PubMed Web of Science ®Google Scholar
• Roth J, Dittmer D, Rea D, et al. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A. 1996;93(10):4781–4786.
   PubMed Web of Science ®Google Scholar
• Singh P, Pal SK, Alex A, et al. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol. 2015;11(15):2137–2148.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325–1333.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS. Talimogene laherparepvec for the treatment of advanced melanoma. Clin Cancer Res. 2016;22(13):3127–3131.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–2088.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Mander A, Chudley L, et al. DNA fusion vaccines enter the clinic. Cancer Immunol Immunother. 2011;60(8):1147–1151.
   PubMed Web of Science ®Google Scholar
• Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009;32(5):498–507.
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19(5):990–999.
   PubMed Web of Science ®Google Scholar
• Hong Y, Peng Y, Guo ZS, et al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology. 2014;59(4):1448–1458.
   PubMed Web of Science ®Google Scholar
• Duperret EK, Liu S, Paik M, et al. A designer cross-reactive DNA immunotherapeutic vaccine that targets multiple MAGE-A family members simultaneously for cancer therapy. Clin Cancer Res. 2018;24(23):6015–6027.
   PubMed Web of Science ®Google Scholar
• Oran AE, Robinson HL. DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells. J Immunol. 2003;171(4):1999–2005.
   PubMed Web of Science ®Google Scholar
• Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–229.
   PubMed Web of Science ®Google Scholar
• Duong HTT, Yin Y, Thambi T, et al. Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy. Biomaterials. 2018;185:13–24.
   PubMed Web of Science ®Google Scholar
• Pyzer AR, Avigan DE, Rosenblatt J. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother. 2014;10(11):3125–3131.
   PubMed Web of Science ®Google Scholar
• Wei XX, Perry J, Chang E, et al. Clinical variables associated with overall survival in metastatic castration-resistant prostate cancer patients treated with sipuleucel-T immunotherapy. Clin Genitourin Cancer. 2018;16(3):184–190 e182.
   PubMed Web of Science ®Google Scholar
• Zhang W, Lu X, Cui P, et al. Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother. 2019;68(1):121–130.
   PubMed Web of Science ®Google Scholar
• Geskin LJ, Damiano JJ, Patrone CC, et al. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018;28(3):211–221.
   PubMed Web of Science ®Google Scholar
• Reap EA, Suryadevara CM, Batich KA, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma. Cancer Res. 2018;78(1):256–264.
   PubMed Web of Science ®Google Scholar
• Laurell A, Lonnemark M, Brekkan E, et al. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer. 2017;5(52): DOI:10.1186/s40425-017-0255-0
   PubMed Web of Science ®Google Scholar
• Sprooten J, Ceusters J, Coosemans A, et al. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019;8(11):e1638212.
   PubMed Web of Science ®Google Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195–1203.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, De Vries IJ, Torensma R, et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7(10):790–802.
   PubMed Web of Science ®Google Scholar
• Fotaki G, Jin C, Ramachandran M, et al. Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology. 2018;7(3):e1395126.
   PubMed Web of Science ®Google Scholar
• Mehrotra S, Britten CD, Chin S, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017;10(1):82.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, Ota S. Vaccination of urological cancer patients with WT1 peptide-pulsed dendritic cells in combination with molecular targeted therapy or conventional chemotherapy induces immunological and clinical responses. Ther Apheresis Dialysis. 2018;22(3):266–277.
   PubMed Web of Science ®Google Scholar
• Hijikata Y, Okazaki T, Tanaka Y, et al. A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018;13(1):e0187878.
   PubMed Web of Science ®Google Scholar
• Inoges S, Tejada S, De Cerio AL, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15(1):104.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–167.
   PubMed Web of Science ®Google Scholar
• Herbert GS, Vreeland TJ, Clifton GT, et al. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. Vaccine. 2018;36(23):3247–3253.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Kibel AS, Yu EY, et al. Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: a phase II randomized trial. Clin Cancer Res. 2017;23(10):2451–2459.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, McMannis JD, Bai Y, et al. Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. Cancer Immunol Immunother. 2017;66(10):1345–1357.
   PubMed Web of Science ®Google Scholar
• Yao Y, Luo F, Tang C, et al. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother. 2018;67(11):1777–1788.
   PubMed Web of Science ®Google Scholar
• Batich KA, Reap EA, Archer GE, et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res. 2017;23(8):1898–1909.
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A. 2011;108(6):2384–2389.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–112.
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. Npj Vaccines. 2019;4(1):7.
   PubMed Web of Science ®Google Scholar
• Tran T, Blanc C, Granier C, et al. Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol. 2019;41(1):69–85.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Fortis SP, Ardavanis A, et al. Exploring essential issues for improving therapeutic cancer vaccine trial design. Cancers (Basel). 2020;12(10):2908.
   Web of Science ®Google Scholar
• Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–245.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Tran E, Ahmadzadeh M, Y-c L, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–1390.
   PubMed Web of Science ®Google Scholar
• Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–239.
   PubMed Web of Science ®Google Scholar
• Hacohen N, Fritsch EF, Carter TA, et al. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013;1(1):11–15.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–5337.
   PubMed Web of Science ®Google Scholar
• Pearson FE, Tullett KM, Leal-Rojas IM et al. Human CLEC9A antibodies deliver Wilms’ tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1-specific CD8+ T cells. Clin Transl Immunology. 2020;9(6):e1141.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
   PubMed Web of Science ®Google Scholar
• Srivastava PK, Duan F. Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunol Immunother. 2013;62(5):967–974.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, Van De Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692–696.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221.
   PubMed Web of Science ®Google Scholar
• Zhang W, He H, Zang M, et al. Genetic features of aflatoxin-associated hepatocellular carcinoma. Gastroenterology. 2017;153(1):249–262.e242.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Hikichi T, Onishi H, et al. Intranodal administration of neoantigen peptide-loaded dendritic cell vaccine elicits epitope-specific T cell responses and clinical effects in a patient with chemorefractory ovarian cancer with malignant ascites. Immunol Invest. 2020; 1–18. DOI:10.1080/08820139.2020.1778721
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Noguchi E, Bando H, et al. Neoantigen prediction in human breast cancer using RNA sequencing data. Cancer Sci. 2020;112(1):465–475.
   PubMed Web of Science ®Google Scholar
• Aqbi HF, Coleman C, Zarei M, et al. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets. Breast Cancer Res. 2020;22(1):116.
   PubMed Web of Science ®Google Scholar
• Sena LA, Fountain J, Isaacsson Velho P, et al. Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. Oncologist. 2020;26(2):e270-e278.
   PubMed Web of Science ®Google Scholar
• Abdul Sater H, Marte JL, Donahue RN, et al. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. J Immunother Cancer. 2020;8(1):e000655.
   PubMed Web of Science ®Google Scholar
• Shahnazari M, Samadi P, Pourjafar M, et al. Therapeutic vaccines for colorectal cancer: the progress and future prospect. Int Immunopharmacol. 2020;88(106944):106944.
   PubMed Web of Science ®Google Scholar
• Zhang J, Shen L, Johnston SA. Using frameshift peptide arrays for cancer neo-antigens screening. Sci Rep. 2018;8(1):17366.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226.
   PubMed Web of Science ®Google Scholar
• Fang Y, Mo F, Shou J, et al. A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors. Clin Cancer Res. 2020; clincanres.2881.2019. DOI:10.1158/1078-0432.CCR-19-2881
   Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347–362 e324.
   PubMed Web of Science ®Google Scholar
• Liu XS, Mardis ER. Applications of Immunogenomics to Cancer. Cell. 2017;168(4):600–612.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–808.
   PubMed Web of Science ®Google Scholar
• Harari A, Graciotti M, Bassani-Sternberg M, et al. Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery. 2020;19(9):635–652.
   PubMed Web of Science ®Google Scholar
• Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018;10(436):eaao5931.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to t-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057–5069.
   PubMed Web of Science ®Google Scholar
• Smith C, Chang MY, Parker KH, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012;2(8):722–735.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212–1218.
   PubMed Web of Science ®Google Scholar
• Schildberg FA, Klein SR, Freeman GJ, et al. Coinhibitory Pathways in the B7-CD28 ligand-receptor family. Immunity. 2016;44(5):955–972.
   PubMed Web of Science ®Google Scholar
• Li J, Lee Y, Li Y, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T Cells. Immunity. 2018;48(4):773–786.e775.
   PubMed Web of Science ®Google Scholar
• Fu J, Kanne DB, Leong M, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra252.
   Web of Science ®Google Scholar
• Ali OA, Lewin SA, Dranoff G, et al. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication. Cancer Immunol Res. 2016;4(2):95–100.
   PubMed Web of Science ®Google Scholar
• Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical Trial. JAMA Oncol. 2019;5(1):67–73.
   PubMed Web of Science ®Google Scholar
• Romano E, Michielin O, Voelter V, et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med. 2014;12(97):97.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–2127.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shao Z, Gao J. Antitumor effect of a DNA vaccine harboring prostate cancer-specific antigen with IL-12 as an intramolecular adjuvant. J Mol Microbiol Biotechnol. 2017;27(3):168–174.
   PubMed Web of Science ®Google Scholar
• Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016;4(56). DOI:10.1186/s40425-016-0160-y
   PubMed Web of Science ®Google Scholar
• Kumai T, Kobayashi H, Harabuchi Y, et al. Peptide vaccines in cancer-old concept revisited. Curr Opin Immunol. 2017;45:1–7.
   PubMed Web of Science ®Google Scholar
• Cadena A, Tr C, Anderson C, et al. Radiation and anti-cancer vaccines: a winning combination. Vaccines (Basel). 2018;6(1):9.
   PubMed Web of Science ®Google Scholar
• Quoix E, Lena H, Losonczy G, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17(2):212–223.
   PubMed Web of Science ®Google Scholar
• Nagai K, Adachi T, Harada H, et al. Dendritic cell-based immunotherapy pulsed with wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I/IIa clinical trial. Anticancer Res. 2020;40(10):5765–5776.
   PubMed Web of Science ®Google Scholar
• Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2020. DOI:10.1016/j.semcancer.2020.08.017
   PubMed Web of Science ®Google Scholar
• Neon therapeutics’ personal neoantigen vaccine study demonstrates prolonged progression-free survival in advanced or metastatic melanoma, non-small cell lung and bladder cancers. Retrieved Jul 15, 2019, from https://www.globenewswire.com/news-release/2019/07/15/1882432/0/en/Neon-Therapeutics-Personal-Neoantigen-Vaccine-Study-Demonstrates-Prolonged-Progression-Free-Survival-in-Advanced-or-Metastatic-Melanoma-Non-Small-Cell-Lung-and-Bladder-Cancers.html.).
   Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4(7). DOI:10.1038/s41541-019-0103-y
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–112.
   PubMed Web of Science ®Google Scholar
• Bordon BY. An RNA vaccine for advanced melanoma. Nature Reviews Immunology. 2020;20(9):517.
   PubMed Web of Science ®Google Scholar
• Kyi C, Roudko V, Sabado R, et al. Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial. Clin Cancer Res. 2018;24(20):4937–4948.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3(e28780):e28780.
   PubMed Web of Science ®Google Scholar
• Wang X, Schoenhals JE, Li A, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 2017;77(4):839–850.
   PubMed Web of Science ®Google Scholar